Trial of Anifrolumab in Active Systemic Lupus Erythematosus

A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. A previous phase 3 trial failed to meet its primary objective but showed an effect in secondary end points.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-01, Vol.382 (3), p.211-221
Hauptverfasser:	Morand, Eric F, Furie, Richard, Tanaka, Yoshiya, Bruce, Ian N, Askanase, Anca D, Richez, Christophe, Bae, Sang-Cheol, Brohawn, Philip Z, Pineda, Lilia, Berglind, Anna, Tummala, Raj
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Bronchitis Double-Blind Method Female Glucocorticoids Glucocorticoids - therapeutic use Herpes zoster Humans Immunoglobulins Immunosuppressive agents Infusions, Intravenous Interferon Intravenous administration Laboratories Lupus Lupus Erythematosus, Systemic - drug therapy Male Middle Aged Monoclonal antibodies Receptor, Interferon alpha-beta - antagonists & inhibitors Severity of Illness Index Skin diseases Statistical analysis Systemic lupus erythematosus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. A previous phase 3 trial failed to meet its primary objective but showed an effect in secondary end points.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1912196